Literature DB >> 28548122

Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.

Alessandro Lugli1, Richard Kirsch2, Yoichi Ajioka3, Fred Bosman4, Gieri Cathomas5, Heather Dawson1, Hala El Zimaity6, Jean-François Fléjou7, Tine Plato Hansen8, Arndt Hartmann9, Sanjay Kakar10, Cord Langner11, Iris Nagtegaal12, Giacomo Puppa13, Robert Riddell2, Ari Ristimäki14, Kieran Sheahan15, Thomas Smyrk16, Kenichi Sugihara17, Benoît Terris18, Hideki Ueno19, Michael Vieth20, Inti Zlobec1, Phil Quirke21.   

Abstract

Tumor budding is a well-established independent prognostic factor in colorectal cancer but a standardized method for its assessment has been lacking. The primary aim of the International Tumor Budding Consensus Conference (ITBCC) was to reach agreement on an international, evidence-based standardized scoring system for tumor budding in colorectal cancer. The ITBCC included nine sessions with presentations, a pre-meeting survey and an e-book covering the key publications on tumor budding in colorectal cancer. The 'Grading of Recommendation Assessment, Development and Evaluation' method was used to determine the strength of recommendations and quality of evidence. The following 10 statements achieved consensus: tumor budding is defined as a single tumor cell or a cell cluster consisting of four tumor cells or less (22/22, 100%). Tumor budding is an independent predictor of lymph node metastases in pT1 colorectal cancer (23/23, 100%). Tumor budding is an independent predictor of survival in stage II colorectal cancer (23/23, 100%). Tumor budding should be taken into account along with other clinicopathological features in a multidisciplinary setting (23/23, 100%). Tumor budding is counted on H&E (19/22, 86%). Intratumoral budding exists in colorectal cancer and has been shown to be related to lymph node metastasis (22/22, 100%). Tumor budding is assessed in one hotspot (in a field measuring 0.785 mm2) at the invasive front (22/22, 100%). A three-tier system should be used along with the budding count in order to facilitate risk stratification in colorectal cancer (23/23, 100%). Tumor budding and tumor grade are not the same (23/23, 100%). Tumor budding should be included in guidelines/protocols for colorectal cancer reporting (23/23, 100%). Members of the ITBCC were able to reach strong consensus on a single international, evidence-based method for tumor budding assessment and reporting. It is proposed that this method be incorporated into colorectal cancer guidelines/protocols and staging systems.

Entities:  

Mesh:

Year:  2017        PMID: 28548122     DOI: 10.1038/modpathol.2017.46

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  89 in total

Review 1.  Systematic review and meta-analysis of histopathological predictive factors for lymph node metastasis in T1 colorectal cancer.

Authors:  Hiroo Wada; Manabu Shiozawa; Kayoko Katayama; Naoyuki Okamoto; Yohei Miyagi; Yasushi Rino; Munetaka Masuda; Makoto Akaike
Journal:  J Gastroenterol       Date:  2015-03-01       Impact factor: 7.527

2.  GRADE guidelines: 5. Rating the quality of evidence--publication bias.

Authors:  Gordon H Guyatt; Andrew D Oxman; Victor Montori; Gunn Vist; Regina Kunz; Jan Brozek; Pablo Alonso-Coello; Ben Djulbegovic; David Atkins; Yngve Falck-Ytter; John W Williams; Joerg Meerpohl; Susan L Norris; Elie A Akl; Holger J Schünemann
Journal:  J Clin Epidemiol       Date:  2011-07-30       Impact factor: 6.437

Review 3.  Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis.

Authors:  F Petrelli; E Pezzica; M Cabiddu; A Coinu; K Borgonovo; M Ghilardi; V Lonati; D Corti; S Barni
Journal:  J Gastrointest Cancer       Date:  2015-09

4.  Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and long-term prognosis.

Authors:  Huann-Sheng Wang; Wen-Yih Liang; Tzu-Chen Lin; Wei-Shone Chen; Jeng-Kae Jiang; Shung-Haur Yang; Shih-Ching Chang; Jen-Kou Lin
Journal:  Dis Colon Rectum       Date:  2005-06       Impact factor: 4.585

5.  Risk factors of nodal involvement in T2 colorectal cancer.

Authors:  Yoshiki Kajiwara; Hideki Ueno; Yojiro Hashiguchi; Hidetaka Mochizuki; Kazuo Hase
Journal:  Dis Colon Rectum       Date:  2010-10       Impact factor: 4.585

6.  Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer.

Authors:  H Ueno; J Murphy; J R Jass; H Mochizuki; I C Talbot
Journal:  Histopathology       Date:  2002-02       Impact factor: 5.087

7.  Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma.

Authors:  Takashi Okuyama; Masatoshi Oya; Hiroshi Ishikawa
Journal:  J Surg Oncol       Date:  2003-05       Impact factor: 3.454

8.  Prognostic value of tumor "budding" in patients with colorectal cancer.

Authors:  K Hase; C Shatney; D Johnson; M Trollope; M Vierra
Journal:  Dis Colon Rectum       Date:  1993-07       Impact factor: 4.585

9.  Pathological changes of advanced lower-rectal cancer by preoperative radiotherapy.

Authors:  Hirokatsu Kinoshita; Toshiaki Watanabe; Akio Yanagisawa; Hirokazu Nagawa; Yo Kato; Tetsuichiro Muto
Journal:  Hepatogastroenterology       Date:  2004 Sep-Oct

10.  Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients.

Authors:  I Zlobec; M Hädrich; H Dawson; V H Koelzer; M Borner; M Mallaev; B Schnüriger; D Inderbitzin; A Lugli
Journal:  Br J Cancer       Date:  2013-12-24       Impact factor: 7.640

View more
  177 in total

1.  Interobserver variability in the H&E-based assessment of tumor budding in pT3/4 colon cancer: does it affect the prognostic relevance?

Authors:  Benedikt Martin; Eva Schäfer; Elzbieta Jakubowicz; Patrick Mayr; Regina Ihringer; Matthias Anthuber; Gerhard Schenkirsch; Tina Schaller; Bruno Märkl
Journal:  Virchows Arch       Date:  2018-04-06       Impact factor: 4.064

2.  Poorly Differentiated Clusters Predict Colon Cancer Recurrence: An In-Depth Comparative Analysis of Invasive-Front Prognostic Markers.

Authors:  Tsuyoshi Konishi; Yoshifumi Shimada; Lik Hang Lee; Marcela S Cavalcanti; Meier Hsu; Jesse Joshua Smith; Garrett M Nash; Larissa K Temple; José G Guillem; Philip B Paty; Julio Garcia-Aguilar; Efsevia Vakiani; Mithat Gonen; Jinru Shia; Martin R Weiser
Journal:  Am J Surg Pathol       Date:  2018-06       Impact factor: 6.394

3.  Tumor budding is an adverse prognostic marker in intestinal-type sinonasal adenocarcinoma and seems to be unrelated to epithelial-mesenchymal transition.

Authors:  Valeria Maffeis; Rocco Cappellesso; Francesca Galuppini; Vincenza Guzzardo; Alessia Zanon; Diego Cazzador; Enzo Emanuelli; Laura Ventura; Alessandro Martini; Ambrogio Fassina
Journal:  Virchows Arch       Date:  2020-01-24       Impact factor: 4.064

4.  Tumour budding predicts increased recurrence after curative resection for T2N0 colorectal cancer

Authors:  Richard Garfinkle; Lawrence Lee; Marylise Boutros; Marie-Josee Cardin; Alan Spatz; Nancy Morin
Journal:  Can J Surg       Date:  2019-10-01       Impact factor: 2.089

5.  Spatial immune profiling of the colorectal tumor microenvironment predicts good outcome in stage II patients.

Authors:  Ines P Nearchou; Bethany M Gwyther; Elena C T Georgiakakis; Christos G Gavriel; Kate Lillard; Yoshiki Kajiwara; Hideki Ueno; David J Harrison; Peter D Caie
Journal:  NPJ Digit Med       Date:  2020-05-15

6.  An international survey-based study on colorectal cancer pathology reporting-guidelines versus local practice.

Authors:  Maria Urbanowicz; Heike I Grabsch; Frederic Fiteni; Yan Liu; Carmela Caballero; Jean-François Fléjou
Journal:  Virchows Arch       Date:  2018-09-26       Impact factor: 4.064

7.  Pathologist second opinion significantly alters clinical management of pT1 endoscopically resected colorectal cancer.

Authors:  Gian Luca Rampioni Vinciguerra; Giulio Antonelli; Francesca Citron; Giammauro Berardi; Stefano Angeletti; Gustavo Baldassarre; Andrea Vecchione; Emilio Di Giulio; Emanuela Pilozzi
Journal:  Virchows Arch       Date:  2019-06-17       Impact factor: 4.064

8.  Tumour budding in colorectal cancer: molecular rationale for clinical translation.

Authors:  Inti Zlobec; Alessandro Lugli
Journal:  Nat Rev Cancer       Date:  2018-01-29       Impact factor: 60.716

9.  Tumor Budding Detection System in Whole Slide Pathology Images.

Authors:  Mohammad F A Fauzi; Wei Chen; Debbie Knight; Heather Hampel; Wendy L Frankel; Metin N Gurcan
Journal:  J Med Syst       Date:  2019-12-18       Impact factor: 4.460

Review 10.  [Pathology of early stage cancer of the gastrointestinal tract : Definition, principles and diagnosis].

Authors:  B Märkl; B Martin
Journal:  Chirurg       Date:  2018-05       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.